Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis

Core Insights - Rakovina Therapeutics Inc. is advancing cancer therapies through AI-powered drug discovery and has announced that its Chief Scientific Officer, Dr. Mads Daugaard, will present at the 13th Tuscany Retreat on Cancer Research and Apoptosis [1][2] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments, utilizing unique technologies for targeting the DNA-damage response powered by AI through proprietary platforms like Deep-Docking™ and Enki™ [4][5] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners, establishing a pipeline of distinctive DNA-damage response inhibitors [5] Research and Collaboration - Dr. Daugaard's presentation will cover ongoing research programs at the Vancouver Prostate Centre, including collaborative development programs with Rakovina Therapeutics, highlighting the company's commitment to advancing therapies targeting the DNA-damage response [2][3] - The Tuscany Retreat serves as a platform for collaboration and exchange of ideas among established leaders and the next generation of cancer researchers, emphasizing the importance of such forums in translating discoveries into patient benefits [3][4]